Notablely, CDDP-treated NSCLC patients with high levels of TRIB1 showed a significantly bad response and poorer prognosis, which further confirmed the role of TRIB1 in CDDP resistance. The gene discussed is TRIB1; the disease is non-small cell lung carcinoma.